Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis

Effects of Roxithromycin on Quality of Life and Physiologic Outcomes in Bronchiectasis Patients During Treatment and Posttreatment Period

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04122040

Enrollment

Registered

2019-10-10

Start date

2011-03-01

Completion date

2011-09-30

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of Life, Respiratory Function Tests

Keywords

Bronchiectasis, quality of life, pulmonary function tests

Brief summary

roxithormycin 300 mg per day for 12 weeks could improve quality of life and physiological outcomes in bronchiectasis

Detailed description

A randomized, double blinded, placebo controlled study was conducted to evaluate the effects of a 12-week administration of roxithromycin 300 mg once daily and a 12-week follow-up period in symptomatic stable bronchiectasis

Interventions

DRUGRoxithromycin 300 MG

Roxithromycin 300 mg oral per day

DRUGPlacebo

Placebo one table oral once dialy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Masking description

block of 4

Intervention model description

randomised control study

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

minimum 15 year maximum 75 years Criteria inclusion Criteria: Symptomatic bronchiectasis Stable clinical bronchiectasis

Exclusion criteria

Adverse drug reaction to macrolide Recent exacerbation within 2 weeks History of macrolide therapy within 2 weeks active malignancy and end stage diseases 5. not perform lung function tests Females who were lactating

Design outcomes

Primary

Measure	Time frame	Description
SGRQ scores	for 12 weeks	SGRQ scores

Secondary

Measure	Time frame	Description
pulmonary function tests	24 weeks	FEV1
sputum volumes	24 wekse	sputum volume per day

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026